Nuevolution - six months ahead - six triggers2016-09-29 10:18, Edited at: 2016-09-29 14:46
Please note: Community posts are written by its members and not by Redeye’s research department. As a reader you’re always encouraged to critically analyze the content.
Exciting months ahead for Nuevolution - it is possible all six triggers are in place, and hopefully rock solid, already at year end. It will likely trigger a drastic revaluation of the stock.
Upcoming triggers from small molecule drug discovery engine Nuevolution ( based on public company info - dates are my own estimates based on public company info)
Before end of October 2016
BET inhibitor (selective to BD1) - First in class in inflammation Obtain pre-clinical results from mouse models of very underserved diseases fibrosis (IPF) and Lupus (SLE)
Before end of November 2016
ROR gamma inhibitor - Second/third in class in inflammation / possibly first to inhibit resistance to standard of care in prostate cancer. Obtain late pre-clinical results from serious prostate cancer (CRPC) and undisclosed target in inflammation. Obtain non-GLP tox re the back up candidate.
Before end of December 2016
Cytokine X inhibition - First in class in inflammation Reach lead optimisation stage - possibly release undisclosed target
ROR gamma stimulant - Immune-oncology - compelling new mechanism Obtain data from IL17A/mouse splenocyte stimulation. Opens up for proof of concept 2017
GRP78 inhibitor - First in class in cancer Obtain data for proof of concept in relevant cancer cell lines
Before end of March 2017
Commercial deals - one or two licensing/risk sharing deals expected. Despite being in pre-clinical stage, promising "first/early in class" molecules have the potential to generate commercial deals of high or very high value.